APO Research
Talk to an analyst

APO RESEARCH · REPORT

OX40 Receptor Agonist

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global OX40 Receptor Agonist Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

2 January 2026195 pages

Choose your research edition.

Industry ResearchOX40 Receptor Agonist Industry Research Report 2026128 pages · $2,950 USDIndustry Growth & TrendsGlobal OX40 Receptor Agonist Industry Growth and Trends Forecast to 2032105 pages · $3,450 USDMarket StructureGlobal OX40 Receptor Agonist Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal OX40 Receptor Agonist Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal OX40 Receptor Agonist Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global OX40 Receptor Agonist market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for OX40 Receptor Agonist is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for OX40 Receptor Agonist is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for OX40 Receptor Agonist is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for OX40 Receptor Agonist is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of OX40 Receptor Agonist include Roche, Pfizer, GlaxoSmithKline, Sorrento Therapeutics, Merk, Incyte, Glenmark, Bristol Myers Squibb and Bioinvent, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global OX40 Receptor Agonist market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of OX40 Receptor Agonist and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents OX40 Receptor Agonist sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the OX40 Receptor Agonist market size, projected growth trends, production technologies, key applications, and end-use industries.

OX40 Receptor Agonist Segment by Company

Roche

Pfizer

GlaxoSmithKline

Sorrento Therapeutics

Merk

Incyte

Glenmark

Bristol Myers Squibb

Bioinvent

AstraZeneca (MedImmune)

Agenus

OX40 Receptor Agonist Segment by Type

Fully Human IgG1 Agonist mAb

Fully Human IgG2 Agonist Ab

Humanised IgG1 Agonist mAb

OX40 Receptor Agonist Segment by Application

Myasthenia Gravis

Psoriasis

Cancers

OX40 Receptor Agonist Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global OX40 Receptor Agonist market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of OX40 Receptor Agonist and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of OX40 Receptor Agonist.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the OX40 Receptor Agonist market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of OX40 Receptor Agonist manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of OX40 Receptor Agonist in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of OX40 Receptor Agonist in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. OX40 Receptor Agonist Industry Trends Table 2. OX40 Receptor Agonist Industry Drivers Table 3. OX40 Receptor Agonist Industry Opportunities and Challenges Table 4. OX40 Receptor Agonist Industry Restraints Table 5. Global OX40 Receptor Agonist Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global OX40 Receptor Agonist Revenue Market Share by Manufacturers (2021-2026) Table 7. Global OX40 Receptor Agonist Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global OX40 Receptor Agonist Sales Market Share by Manufacturers Table 9. Global OX40 Receptor Agonist Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global OX40 Receptor Agonist Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global OX40 Receptor Agonist Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global OX40 Receptor Agonist Manufacturers, Product Type & Application Table 13. Global OX40 Receptor Agonist Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global OX40 Receptor Agonist by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Fully Human IgG1 Agonist mAb Table 17. Major Manufacturers of Fully Human IgG2 Agonist Ab Table 18. Major Manufacturers of Humanised IgG1 Agonist mAb Table 19. Global OX40 Receptor Agonist Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global OX40 Receptor Agonist Sales by Type (2021-2026) & (K Units) Table 21. Global OX40 Receptor Agonist Sales by Type (2027-2032) & (K Units) Table 22. Global OX40 Receptor Agonist Sales Market Share by Type (2021-2026) Table 23. Global OX40 Receptor Agonist Sales Market Share by Type (2027-2032) Table 24. Global OX40 Receptor Agonist Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 25. Global OX40 Receptor Agonist Revenue by Type (2021-2026) & (K Units) Table 26. Global OX40 Receptor Agonist Revenue by Type (2027-2032) & (K Units) Table 27. Global OX40 Receptor Agonist Revenue Market Share by Type (2021-2026) Table 28. Global OX40 Receptor Agonist Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Myasthenia Gravis Table 30. Major Manufacturers of Psoriasis Table 31. Major Manufacturers of Cancers Table 32. Global OX40 Receptor Agonist Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global OX40 Receptor Agonist Sales by Application (2021-2026) & (K Units) Table 34. Global OX40 Receptor Agonist Sales by Application (2027-2032) & (K Units) Table 35. Global OX40 Receptor Agonist Sales Market Share by Application (2021-2026) Table 36. Global OX40 Receptor Agonist Sales Market Share by Application (2027-2032) Table 37. Global OX40 Receptor Agonist Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 38. Global OX40 Receptor Agonist Revenue by Application (2021-2026) & (K Units) Table 39. Global OX40 Receptor Agonist Revenue by Application (2027-2032) & (K Units) Table 40. Global OX40 Receptor Agonist Revenue Market Share by Application (2021-2026) Table 41. Global OX40 Receptor Agonist Revenue Market Share by Application (2027-2032) Table 42. Global OX40 Receptor Agonist Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global OX40 Receptor Agonist Sales by Region (2021-2026) & (K Units) Table 44. Global OX40 Receptor Agonist Sales Market Share by Region (2021-2026) Table 45. Global OX40 Receptor Agonist Sales Forecasted by Region (2027-2032) & (K Units) Table 46. Global OX40 Receptor Agonist Sales Forecasted Market Share by Region (2027-2032) Table 47. North America OX40 Receptor Agonist Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 48. North America OX40 Receptor Agonist Sales by Country (2021-2026) & (K Units) Table 49. North America OX40 Receptor Agonist Sales by Country (2027-2032) & (K Units) Table 50. Europe OX40 Receptor Agonist Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 51. Europe OX40 Receptor Agonist Sales by Country (2021-2026) & (K Units) Table 52. Europe OX40 Receptor Agonist Sales by Country (2027-2032) & (K Units) Table 53. Asia Pacific OX40 Receptor Agonist Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Asia Pacific OX40 Receptor Agonist Sales by Country (2021-2026) & (K Units) Table 55. Asia Pacific OX40 Receptor Agonist Sales by Country (2027-2032) & (K Units) Table 56. South America, Middle East and Africa OX40 Receptor Agonist Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. South America, Middle East and Africa OX40 Receptor Agonist Sales by Country (2021-2026) & (K Units) Table 58. South America, Middle East and Africa OX40 Receptor Agonist Sales by Country (2027-2032) & (K Units) Table 59. Global OX40 Receptor Agonist Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global OX40 Receptor Agonist Revenue by Region (2021-2026) & (US$ Million) Table 61. Global OX40 Receptor Agonist Revenue by Region (2027-2032) & (US$ Million) Table 62. Global OX40 Receptor Agonist Revenue Market Share by Region (2021-2026) Table 63. Global OX40 Receptor Agonist Revenue Market Share by Region (2027-2032) Table 64. Roche Company Information Table 65. Roche Business Overview Table 66. Roche OX40 Receptor Agonist Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Roche OX40 Receptor Agonist Product Portfolio Table 68. Roche Recent Development Table 69. Pfizer Company Information Table 70. Pfizer Business Overview Table 71. Pfizer OX40 Receptor Agonist Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Pfizer OX40 Receptor Agonist Product Portfolio Table 73. Pfizer Recent Development Table 74. GlaxoSmithKline Company Information Table 75. GlaxoSmithKline Business Overview Table 76. GlaxoSmithKline OX40 Receptor Agonist Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. GlaxoSmithKline OX40 Receptor Agonist Product Portfolio Table 78. GlaxoSmithKline Recent Development Table 79. Sorrento Therapeutics Company Information Table 80. Sorrento Therapeutics Business Overview Table 81. Sorrento Therapeutics OX40 Receptor Agonist Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Sorrento Therapeutics OX40 Receptor Agonist Product Portfolio Table 83. Sorrento Therapeutics Recent Development Table 84. Merk Company Information Table 85. Merk Business Overview Table 86. Merk OX40 Receptor Agonist Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Merk OX40 Receptor Agonist Product Portfolio Table 88. Merk Recent Development Table 89. Incyte Company Information Table 90. Incyte Business Overview Table 91. Incyte OX40 Receptor Agonist Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Incyte OX40 Receptor Agonist Product Portfolio Table 93. Incyte Recent Development Table 94. Glenmark Company Information Table 95. Glenmark Business Overview Table 96. Glenmark OX40 Receptor Agonist Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. Glenmark OX40 Receptor Agonist Product Portfolio Table 98. Glenmark Recent Development Table 99. Bristol Myers Squibb Company Information Table 100. Bristol Myers Squibb Business Overview Table 101. Bristol Myers Squibb OX40 Receptor Agonist Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. Bristol Myers Squibb OX40 Receptor Agonist Product Portfolio Table 103. Bristol Myers Squibb Recent Development Table 104. Bioinvent Company Information Table 105. Bioinvent Business Overview Table 106. Bioinvent OX40 Receptor Agonist Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 107. Bioinvent OX40 Receptor Agonist Product Portfolio Table 108. Bioinvent Recent Development Table 109. AstraZeneca (MedImmune) Company Information Table 110. AstraZeneca (MedImmune) Business Overview Table 111. AstraZeneca (MedImmune) OX40 Receptor Agonist Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 112. AstraZeneca (MedImmune) OX40 Receptor Agonist Product Portfolio Table 113. AstraZeneca (MedImmune) Recent Development Table 114. Agenus Company Information Table 115. Agenus Business Overview Table 116. Agenus OX40 Receptor Agonist Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 117. Agenus OX40 Receptor Agonist Product Portfolio Table 118. Agenus Recent Development Table 119. Key Raw Materials Table 120. Raw Materials Key Suppliers Table 121. OX40 Receptor Agonist Distributors List Table 122. OX40 Receptor Agonist Customers List Table 123. Research Programs/Design for This Report Table 124. Authors List of This Report Table 125. Secondary Sources Table 126. Primary Sources List of Figures Figure 1. OX40 Receptor Agonist Product Image Figure 2. Global OX40 Receptor Agonist Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global OX40 Receptor Agonist Market Size (2021-2032) & (US$ Million) Figure 4. Global OX40 Receptor Agonist Sales (2021-2032) & (K Units) Figure 5. Global OX40 Receptor Agonist Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 OX40 Receptor Agonist Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Fully Human IgG1 Agonist mAb Image Figure 9. Fully Human IgG2 Agonist Ab Image Figure 10. Humanised IgG1 Agonist mAb Image Figure 11. Global OX40 Receptor Agonist Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global OX40 Receptor Agonist Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global OX40 Receptor Agonist Sales Market Share by Type (2021-2032) Figure 14. Global OX40 Receptor Agonist Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global OX40 Receptor Agonist Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global OX40 Receptor Agonist Revenue Market Share by Type (2021-2032) Figure 17. Myasthenia Gravis Image Figure 18. Psoriasis Image Figure 19. Cancers Image Figure 20. Global OX40 Receptor Agonist Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global OX40 Receptor Agonist Sales Market Share 2021 VS 2025 VS 2032 Figure 22. Global OX40 Receptor Agonist Sales Market Share by Application (2021-2032) Figure 23. Global OX40 Receptor Agonist Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global OX40 Receptor Agonist Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global OX40 Receptor Agonist Revenue Market Share by Application (2021-2032) Figure 26. North America OX40 Receptor Agonist Sales and Growth Rate (2021-2032) & (K Units) Figure 27. North America OX40 Receptor Agonist Sales Market Share by Country (2021-2032) Figure 28. U.S. OX40 Receptor Agonist Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Canada OX40 Receptor Agonist Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Mexico OX40 Receptor Agonist Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe OX40 Receptor Agonist Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Europe OX40 Receptor Agonist Sales Market Share by Country (2021-2032) Figure 33. Germany OX40 Receptor Agonist Sales and Growth Rate (2021-2032) & (K Units) Figure 34. France OX40 Receptor Agonist Sales and Growth Rate (2021-2032) & (K Units) Figure 35. U.K. OX40 Receptor Agonist Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Italy OX40 Receptor Agonist Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Netherlands OX40 Receptor Agonist Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific OX40 Receptor Agonist Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Asia Pacific OX40 Receptor Agonist Sales Market Share by Country (2021-2032) Figure 40. China OX40 Receptor Agonist Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Japan OX40 Receptor Agonist Sales and Growth Rate (2021-2032) & (K Units) Figure 42. South Korea OX40 Receptor Agonist Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Southeast Asia OX40 Receptor Agonist Sales and Growth Rate (2021-2032) & (K Units) Figure 44. India OX40 Receptor Agonist Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Australia OX40 Receptor Agonist Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa OX40 Receptor Agonist Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South America, Middle East and Africa OX40 Receptor Agonist Sales Market Share by Country (2021-2032) Figure 48. Brazil OX40 Receptor Agonist Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South Africa OX40 Receptor Agonist Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Saudi Arabia OX40 Receptor Agonist Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Turkey OX40 Receptor Agonist Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Argentina OX40 Receptor Agonist Sales and Growth Rate (2021-2032) & (K Units) Figure 53. UAE OX40 Receptor Agonist Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Egypt OX40 Receptor Agonist Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Chile OX40 Receptor Agonist Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Global OX40 Receptor Agonist Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Global OX40 Receptor Agonist Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 58. North America OX40 Receptor Agonist Revenue (2021-2032) & (US$ Million) Figure 59. North America OX40 Receptor Agonist Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Europe OX40 Receptor Agonist Revenue (2021-2032) & (US$ Million) Figure 61. Europe OX40 Receptor Agonist Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific OX40 Receptor Agonist Revenue (2021-2032) & (US$ Million) Figure 63. Asia-Pacific OX40 Receptor Agonist Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. South America, Middle East and Africa OX40 Receptor Agonist Revenue (2021-2032) & (US$ Million) Figure 65. South America, Middle East and Africa OX40 Receptor Agonist Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. OX40 Receptor Agonist Value Chain Figure 67. Manufacturing Cost Structure Figure 68. OX40 Receptor Agonist Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Fully Human IgG1 Agonist mAb
  • Fully Human IgG2 Agonist Ab
  • Humanised IgG1 Agonist mAb
Applications
  • Myasthenia Gravis
  • Psoriasis
  • Cancers
Companies covered
  • Roche
  • Pfizer
  • GlaxoSmithKline
  • Sorrento Therapeutics
  • Merk
  • Incyte
  • Glenmark
  • Bristol Myers Squibb
  • Bioinvent
  • AstraZeneca (MedImmune)
  • Agenus

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global OX40 Receptor Agonist Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global OX40 Receptor Agonist Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global OX40 Receptor Agonist Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global OX40 Receptor Agonist Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global OX40 Receptor Agonist Market Dynamics
  1. 2.1 OX40 Receptor Agonist Industry Trends
  2. 2.2 OX40 Receptor Agonist Industry Drivers
  3. 2.3 OX40 Receptor Agonist Industry Opportunities and Challenges
  4. 2.4 OX40 Receptor Agonist Industry Restraints
3 OX40 Receptor Agonist Market by Manufacturers
  1. 3.1 Global OX40 Receptor Agonist Revenue by Manufacturers (2021-2026)
  2. 3.2 Global OX40 Receptor Agonist Sales by Manufacturers (2021-2026)
  3. 3.3 Global OX40 Receptor Agonist Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global OX40 Receptor Agonist Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global OX40 Receptor Agonist Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global OX40 Receptor Agonist Manufacturers, Product Type & Application
  7. 3.7 Global OX40 Receptor Agonist Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global OX40 Receptor Agonist Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 OX40 Receptor Agonist Players Market Share by Revenue in 2025
  11. 3.8.3 2025 OX40 Receptor Agonist Tier 1, Tier 2, and Tier 3
4 OX40 Receptor Agonist Market by Type
  1. 4.1 OX40 Receptor Agonist Type Introduction
  2. 4.1.1 Fully Human IgG1 Agonist mAb
  3. 4.1.2 Fully Human IgG2 Agonist Ab
  4. 4.1.3 Humanised IgG1 Agonist mAb
  5. 4.2 Global OX40 Receptor Agonist Sales by Type
  6. 4.2.1 Global OX40 Receptor Agonist Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global OX40 Receptor Agonist Sales by Type (2021-2032)
  8. 4.2.3 Global OX40 Receptor Agonist Sales Market Share by Type (2021-2032)
  9. 4.3 Global OX40 Receptor Agonist Revenue by Type
  10. 4.3.1 Global OX40 Receptor Agonist Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global OX40 Receptor Agonist Revenue by Type (2021-2032)
  12. 4.3.3 Global OX40 Receptor Agonist Revenue Market Share by Type (2021-2032)
5 OX40 Receptor Agonist Market by Application
  1. 5.1 OX40 Receptor Agonist Application Introduction
  2. 5.1.1 Myasthenia Gravis
  3. 5.1.2 Psoriasis
  4. 5.1.3 Cancers
  5. 5.2 Global OX40 Receptor Agonist Sales by Application
  6. 5.2.1 Global OX40 Receptor Agonist Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global OX40 Receptor Agonist Sales by Application (2021-2032)
  8. 5.2.3 Global OX40 Receptor Agonist Sales Market Share by Application (2021-2032)
  9. 5.3 Global OX40 Receptor Agonist Revenue by Application
  10. 5.3.1 Global OX40 Receptor Agonist Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global OX40 Receptor Agonist Revenue by Application (2021-2032)
  12. 5.3.3 Global OX40 Receptor Agonist Revenue Market Share by Application (2021-2032)
6 Global OX40 Receptor Agonist Sales by Region
  1. 6.1 Global OX40 Receptor Agonist Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global OX40 Receptor Agonist Sales by Region (2021-2032)
  3. 6.2.1 Global OX40 Receptor Agonist Sales by Region (2021-2026)
  4. 6.2.2 Global OX40 Receptor Agonist Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America OX40 Receptor Agonist Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America OX40 Receptor Agonist Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe OX40 Receptor Agonist Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe OX40 Receptor Agonist Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific OX40 Receptor Agonist Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific OX40 Receptor Agonist Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa OX40 Receptor Agonist Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa OX40 Receptor Agonist Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global OX40 Receptor Agonist Revenue by Region
  1. 7.1 Global OX40 Receptor Agonist Revenue by Region
  2. 7.1.1 Global OX40 Receptor Agonist Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global OX40 Receptor Agonist Revenue by Region (2021-2026)
  4. 7.1.3 Global OX40 Receptor Agonist Revenue by Region (2027-2032)
  5. 7.1.4 Global OX40 Receptor Agonist Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America OX40 Receptor Agonist Revenue (2021-2032)
  8. 7.2.2 North America OX40 Receptor Agonist Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe OX40 Receptor Agonist Revenue (2021-2032)
  11. 7.3.2 Europe OX40 Receptor Agonist Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific OX40 Receptor Agonist Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific OX40 Receptor Agonist Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa OX40 Receptor Agonist Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa OX40 Receptor Agonist Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Roche
  2. 8.1.1 Roche Company Information
  3. 8.1.2 Roche Business Overview
  4. 8.1.3 Roche OX40 Receptor Agonist Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Roche OX40 Receptor Agonist Product Portfolio
  6. 8.1.5 Roche Recent Developments
  7. 8.2 Pfizer
  8. 8.2.1 Pfizer Company Information
  9. 8.2.2 Pfizer Business Overview
  10. 8.2.3 Pfizer OX40 Receptor Agonist Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Pfizer OX40 Receptor Agonist Product Portfolio
  12. 8.2.5 Pfizer Recent Developments
  13. 8.3 GlaxoSmithKline
  14. 8.3.1 GlaxoSmithKline Company Information
  15. 8.3.2 GlaxoSmithKline Business Overview
  16. 8.3.3 GlaxoSmithKline OX40 Receptor Agonist Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 GlaxoSmithKline OX40 Receptor Agonist Product Portfolio
  18. 8.3.5 GlaxoSmithKline Recent Developments
  19. 8.4 Sorrento Therapeutics
  20. 8.4.1 Sorrento Therapeutics Company Information
  21. 8.4.2 Sorrento Therapeutics Business Overview
  22. 8.4.3 Sorrento Therapeutics OX40 Receptor Agonist Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Sorrento Therapeutics OX40 Receptor Agonist Product Portfolio
  24. 8.4.5 Sorrento Therapeutics Recent Developments
  25. 8.5 Merk
  26. 8.5.1 Merk Company Information
  27. 8.5.2 Merk Business Overview
  28. 8.5.3 Merk OX40 Receptor Agonist Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Merk OX40 Receptor Agonist Product Portfolio
  30. 8.5.5 Merk Recent Developments
  31. 8.6 Incyte
  32. 8.6.1 Incyte Company Information
  33. 8.6.2 Incyte Business Overview
  34. 8.6.3 Incyte OX40 Receptor Agonist Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Incyte OX40 Receptor Agonist Product Portfolio
  36. 8.6.5 Incyte Recent Developments
  37. 8.7 Glenmark
  38. 8.7.1 Glenmark Company Information
  39. 8.7.2 Glenmark Business Overview
  40. 8.7.3 Glenmark OX40 Receptor Agonist Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Glenmark OX40 Receptor Agonist Product Portfolio
  42. 8.7.5 Glenmark Recent Developments
  43. 8.8 Bristol Myers Squibb
  44. 8.8.1 Bristol Myers Squibb Company Information
  45. 8.8.2 Bristol Myers Squibb Business Overview
  46. 8.8.3 Bristol Myers Squibb OX40 Receptor Agonist Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Bristol Myers Squibb OX40 Receptor Agonist Product Portfolio
  48. 8.8.5 Bristol Myers Squibb Recent Developments
  49. 8.9 Bioinvent
  50. 8.9.1 Bioinvent Company Information
  51. 8.9.2 Bioinvent Business Overview
  52. 8.9.3 Bioinvent OX40 Receptor Agonist Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Bioinvent OX40 Receptor Agonist Product Portfolio
  54. 8.9.5 Bioinvent Recent Developments
  55. 8.10 AstraZeneca (MedImmune)
  56. 8.10.1 AstraZeneca (MedImmune) Company Information
  57. 8.10.2 AstraZeneca (MedImmune) Business Overview
  58. 8.10.3 AstraZeneca (MedImmune) OX40 Receptor Agonist Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 AstraZeneca (MedImmune) OX40 Receptor Agonist Product Portfolio
  60. 8.10.5 AstraZeneca (MedImmune) Recent Developments
  61. 8.11 Agenus
  62. 8.11.1 Agenus Company Information
  63. 8.11.2 Agenus Business Overview
  64. 8.11.3 Agenus OX40 Receptor Agonist Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Agenus OX40 Receptor Agonist Product Portfolio
  66. 8.11.5 Agenus Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 OX40 Receptor Agonist Value Chain Analysis
  2. 9.1.1 OX40 Receptor Agonist Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 OX40 Receptor Agonist Production Mode & Process
  6. 9.2 OX40 Receptor Agonist Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 OX40 Receptor Agonist Distributors
  9. 9.2.3 OX40 Receptor Agonist Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst